BNB Plus (DE:UDJ1)
FRANKFURT:UDJ1
UDJ1 Stock Chart & Stats
€1.78
--
Market closed
€1.78
--
Day’s Range― - ―
52-Week Range€0.24 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)19.00
Market Cap
€3.11M
Enterprise Value-€393.81K
Total Cash (Recent Filing)€949.09K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-39.93
Shares Outstanding7,197,228
10 Day Avg. Volume0
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-70.32
Revenue Forecast (FY)€6.31M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Equity BaseMinimal debt and a materially larger equity base reduce refinancing and solvency risk, preserving strategic optionality. This stronger capitalization gives management time to pursue asset monetization or restructurings without immediate debt pressure, supporting durable financial flexibility.
Material TTM Revenue ReboundA near-200% TTM revenue rebound signals meaningful commercial traction or revenue recognition events that could persist. If management controls the cost base, sustained top-line momentum can underpin scaling, monetization of LineaRx, and long-term recovery in operating leverage.
Committed Preferred-stock Financing Provides RunwayA structured $5M financing (initial $4.1M committed) with senior preferred terms and conversion options materially extends runway and reduces immediate dilution risk. This capital supports a strategic review and potential monetization steps, enabling longer-term value-creation options.
Bears Say
Severe Negative Cash Flow / High BurnSustained negative operating and free cash flow near $13.8M per TTM exhausts liquidity and forces repeated financing or asset sales. High cash burn elevates execution and dilution risk, constraining the company's ability to fund R&D, commercialization, or strategic investments over months.
Extreme Operating And Net LossesDeep negative margins indicate the business remains far from break-even and that current revenue growth hasn't translated into profitable operations. Persistent extreme losses erode equity, signal scale or cost-structure problems, and make long-term viability contingent on major restructuring or divestiture.
Nasdaq Delisting And Listing UncertaintyFormal delisting risk and ineligibility for a standard compliance cure raise durable concerns about liquidity, investor access, and the firm's ability to raise capital. Listing uncertainty can impair partnerships, employee retention, and long-term funding prospects if not resolved.
BNB Plus News
UDJ1 FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was €0.24 and its highest was €6.00 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is €3.11M.
When is BNB Plus’s upcoming earnings report date?
BNB Plus’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.
How were BNB Plus’s earnings last quarter?
BNB Plus released its earnings results on May 07, 2026. The company reported -€0.594 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.594.
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 7,197,228 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
BNB Plus reported an EPS of -€0.594 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.593%.
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in DE:UDJ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―
Options Prices
Currently, No data available
---